Abstract
Some diazaphosphorinanes were synthesized and characterized by 1H, 13C, 31P NMR and IR spectroscopy and elemental analysis. The antitumor activity of cyclophosphamide (CP) and its nine analogoues with formula , R = OC6H5CH3-4 (1), NHC6H4S(O)2NH2-4 (2), NHC(O)NHC6H4-CH3-2 (3), NHC(O)NHC6H4-NO2-2 (4), NHC(O)NHC6H4-NO2-3 (5), NHC(O)NHC6H4-NO2-4 (6), NHC(O)C6H4-NO2-2 (7), NHC(O)C6H4-NO2-3 (8), and NHC(O)C6H4-NO2-4 (9) were evaluated by cell culture on K562 cell line using MTT cell proliferation assay. The IC50 values for CP and the compounds 1–9 were in the range of 0.140 (for 3) to 58.250 μM (for 2). It was found that compounds 3–6 are the best candidates for antitumor activity close to CP. Compound 2 containing aminosulfonamide substituent is very much less toxic among these compounds.
Similar content being viewed by others
References
Baldwin A, Huang Z, Jounaidi Y, Waxman DJ (2003) Identification of novel enzyme–prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Archives Biochem Biophys 409:197–206. doi:10.1016/S0003-9861(02)00453-8
Billman JH, Meisenheimer JL, Awl RA (1964) 1,3,2-Diazaphosphorinane 2-oxides. 1. Synthesis of some 2-(N-arylamino)-1,3,2-diazaphosphorinane 2-oxides. J Med Chem 7:366–367. doi:10.1021/jm00333a032
Borch RF, Canute GW (1991) Synthesis and antitumor properties of activated cyclophosphamide analogues. J Med Chem 34:3044–3052. doi:10.1021/jm00114a013
Borch RF, Millard JA (1987) The mechanism of activation of 4-hydroxycyclophosphamide. J Med Chem 30:427–431. doi:10.1021/jm00385a029
Borch RF, Liu J, Joswig C, Baggs RB, Dexter DL, Mangold GL (2001) Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates. J Med Chem 44:74–77. doi:10.1021/jm000359y
D’Agostini C, Pica F, Febbraro G, Grelli S, Chiavaroli C, Garaci E (2005) Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol 5:1205–1212. doi:10.1016/j.intimp.2005.02.013
Eliel E, Hutchins RO (1969) Conformational Analysis. XVIII. 1,3-dithianes. Conformational preferences of alkyl substituents and the chair-boat energy difference. J Am Chem Soc 91:2703–2715. doi:10.1021/ja01038a050
Flader C, Liu J, Borch RF (2000) Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase. J Med Chem 43:3157–3167. doi:10.1021/jm000179o
Gholivand K, Shariatinia Z, Pourayoubi M, Farshadian S (2005a) Syntheses and spectroscopic study of some new diazaphospholes and diazaphosphorinanes; crystal structure of . Z Naturforsch 60b:1021–1026
Gholivand K, Pourayoubi M, Farshadian S, Molani S, Shariatinia Z (2005b) Synthesis and crystal structure of 5, 5-dimethyl-2-(p-methylanilino)-2-oxo-1,3,2-diazaphosphorinane. Anal Sci 21:x55. doi:10.2116/analscix.21.x55
Gholivand K, Pourayoubi M, Shariatinia Z (2007) 2, 3J(P, X) [X = H, C] coupling constants dependency to the ring size, hybridization and substituents in new diazaphospholes and diazaphosphorinanes, NMR and X-ray crystallography studies. Polyhedron 26:837–844. doi:10.1016/j.poly.2006.09.092
Gholivand K, Dorosti N (2010) Synthesis, spectroscopic characterization, crystal structure, theoretical studies and antibacterial evaluation of two novel N-phosphinyl urease. Monatshefte Chemie-Chemical Monthly
Gholivand K, Mostaanzadeh H, Vedova COD (2010) J Mol Struct, in preparation
Hansch C, Muir RM, Fujita T, Maloney PP, Geiger F, Streich M (1963) The correlation of biological activity of plant growth regulators and chloromycetin derivatives with Hammett constants and partition coefficients. J Am Chem Soc 85:2817–2824. doi:10.1021/ja00901a033
Jackman LM, Sternhell S (1969) Nuclear magnetic resonance spectroscopy in organic applications of chemistry. Pergamon Press, London, pp 238–240
Jian M, Kwon C-H (2003) 1,2-Benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation. J Med Chem 46:5428–5436. doi:10.1021/jm020581y
Khalikova TA, Ya Zhanaeva S, Korolenko TA, Kaledin VI, Kogan G (2005) Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide. Cancer Lett 223:77–83. doi:10.1016/j.canlet.2004.10.028
Li Z, Han J, Jiang Y, Browne P, Knox RJ, Hu L (2003) Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture. Bioorg Med Chem 11:4171–4178. doi:10.1016/S0968-0896(03)00459-0
Ludeman SM, Zon G, Egan W (1979) Synthesis and antitumor activity of cyclophosphamide analogues. 2.1 Preparation, hydrolytic studies, and anticancer screening of 5-bromocyclophosphamide, 3,5-dehydrocyclophosphamide, and related systems. J Med Chem 22:151–158. doi:10.1021/jm00188a006
McNeish IA, Searle PF, Young LS, Kerr DJ (1997) Gene directed enzyme prodrug therapy for cancer. Adv Drug Deliv Rev 26:173–184. doi:10.1016/S0169-409X(97)00033-1
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63. doi:10.1016/0022-1759(83)90303-4
Niculescu-Duvaz I, Springer CJ (1997) Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv Drug Deliv Rev 26:151–172. doi:10.1016/S0169-409X(97)00032-X
Olyyai R, Stella VJ (1993) Prodrugs of peptides and proteins for improved formulation and delivery. Ann Rev Pharmacol Toxicol 33:521–544. doi:10.1146/annurev.pa.33.040193.002513
Pochopoin NL, Charman WN, Stella VJ (1995) Amino acid derivatives of dapsone as water-soluble prodrugs. Int J Pharm 121:157–167. doi:10.1016/0378-5173(95)00005-4
Reedijk J (1996) Improved understanding in platinium antitumour chemistry. Chem Commun 801–806. doi: 10.1039/CC9960000801
Senter PD, Svensson HP (1996) A summary of monoclonal antibody-enzyme/prodrug. Adv Drug Deliv Rev 22:341–349. doi:10.1016/S0169-409X(96)00445-0
Sherwood RF (1996) Advanced drug delivery reviews: enzyme prodrug therapy. Adv Drug Deliv Rev 22:269–288. doi:10.1016/S0169-409X(96)00450-4
Springer CJ, Niculescu-Duvaz I (1996) Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs. Adv Drug Deliv Rev 22:351–364. doi:10.1016/S0169-409X(96)00449-8
Tobias SC, Borch RF (2001) Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J Med Chem 44:4475–4480. doi:10.1021/jm010337r
Tolkimth H (1959) (Dow Chem. Co., Midland, Mich.). Electron group polarizability and molecular properties of organophosphorus compounds. Ann NY Acad Sci 79:189–232. doi: 10.1111/j.1749-6632.1959.tb42781.x
Software for Windows, GraphPad Software Inc., SanDiego, CA. http://www.graphpad.com
Acknowledgments
We wish to thank the Research Office of Tarbiat Modares University for the financial support of this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gholivand, K., Dorosti, N., Shariatinia, Z. et al. Cyclophosphamide analogues: synthesis, spectroscopic study, and antitumor activity of diazaphosphorinanes. Med Chem Res 20, 1287–1293 (2011). https://doi.org/10.1007/s00044-010-9466-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-010-9466-3